Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotrovimab (Gen1 vs Gen2) in Mild to Moderate COVID-19
NCT04779879Phase 2Completed
- Sponsor
- Vir Biotechnology
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of sotrovimab in coronavirus disease 2019 (COVID-19), sponsored by Vir Biotechnology. Started Feb 2021; status: completed.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04779879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04779879.